Visual impairment and blindness avoided with ranibizumab in hispanic and non-hispanic whites with diabetic macular edema in the United States

Ophthalmology

Volumn 122, Issue 5, 2015, Pages 982-989

  Varma, Rohit ^a   Bressler, Neil M ^b   Doan, Quan V ^c   Danese, Mark ^c   Dolan, Chantal M ^d   Lee, Abraham ^c   Turpcu, Adam ^d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c Outcomes Insight Inc   (United States)

^d GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLINDNESS; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; ETHNIC GROUP; HISPANIC; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MIDDLE AGED; OUTCOME ASSESSMENT; POPULATION; PREVALENCE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; UNITED STATES; VISUAL ACUITY; VISUAL IMPAIRMENT; ANTAGONISTS AND INHIBITORS; CAUCASIAN; DIABETIC RETINOPATHY; EPIDEMIOLOGY; ETHNOLOGY; FEMALE; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MALE; PATIENT; PHYSIOLOGY; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; VERY ELDERLY; VISION, LOW;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BLINDNESS; DIABETIC RETINOPATHY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; MODELS, STATISTICAL; UNITED STATES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISION, LOW; VISUAL ACUITY; VISUALLY IMPAIRED PERSONS;

EID: 84928825571     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2014.12.007     Document Type: Article

References (18)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Available at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2011.pdf. Accessed April 15, 2014.
2. Early Treatment Diabetic Retinopathy Study Research Group Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1 Arch Ophthalmol 103 1985 1796 1806
3. US Department of Health and Human Services; National Eye Institute; National Institutes of Health. Diabetic retinopathy: what you should know [NIH Publication No: 06-2171]. Available at: http://www.nei.nih.gov/health/diabetic/diabeticretino.pdf. Accessed April 15, 2014.
4. M.J. Elman, L.P. Aiello, and R.W. Beck Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema Ophthalmology 117 2010 1064 1077.e35
5. P. Mitchell, F. Bandello, and U. Schmidt-Erfurth The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema Ophthalmology 118 2011 615 625
6. Q.D. Nguyen, D.M. Brown, and D.M. Marcus Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE Ophthalmology 119 2012 789 801
7. US Census Bureau. US Population Projections. National population projections released 2008 (based on Census 2000). Projected population by single year of age, sex, race, and Hispanic origin for the United States: July 1, 2000 to July 1, 2050. Available at: http://www.census.gov/population/projections/data/national/2008.html. Accessed April 13, 2014.
8. Centers for Disease Control and Prevention; National Center for Health Statistics. National Health and Nutrition Examination Survey Data, 2005-2006 and 2007-2008. Available at: http://www.cdc.gov/nchs/nhanes.htm. Accessed April 13, 2014.
9. R. Klein, B.E. Klein, S.E. Moss, and K.J. Cruickshanks The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema Ophthalmology 102 1995 7 16
10. R. Varma, F. Choudhury, and R. Klein Four-year incidence and progression of diabetic retinopathy and macular edema: the Los Angeles Latino Eye Study Am J Ophthalmol 149 2010 752 761.e1-3
11. US Census Bureau. Current Population Survey (CPS) 2011. Current Population Survey (CPS) 2011 table creator. Health insurance coverage for "White alone & Non-Hispanic," and "White alone & Hispanic." Available at: http://www.census.gov/cps/data/cpstablecreator.html. Accessed April 13, 2014.
12. Centers for Disease Control and Prevention. The burden of vision loss. Available at: http://www.cdc.gov/visionhealth/basic-information/vision-loss-burden.htm. Accessed April 13, 2014.
13. Centers for Disease Control and Prevention, National Center for Health Statistics. Life tables. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr58/nvsr58-21.pdf. Accessed April 13, 2014.
14. E.W. Gregg, Q. Gu, and Y.J. Cheng Mortality trends in men and women with diabetes, 1971 to 2000 Ann Intern Med 147 2007 149 155
15. N.M. Bressler, Q.V. Doan, and R. Varma Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-Hispanic white population in the United States with age-related macular degeneration Arch Ophthalmol 129 2011 709 717
16. M.J. Elman, H. Qin, and L.P. Aiello Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results Ophthalmology 119 2012 2312 2318
17. M.J. Elman, A. Ayala, N.M. Bressler Diabetic Retinopathy Clinical Research Network Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results Ophthalmology 122 2015 375 381
18. J.P. Campbell, S.B. Bressler, and N.M. Bressler Impact of availability of anti-vascular endothelial growth factor therapy on visual impairment and blindness due to neovascular age-related macular degeneration Arch Ophthalmol 130 2012 794 795